abstract |
The present invention provides a stable formulation comprising an anti-EGFR antibody drug conjugate (ADC), histidine, a sugar and a surfactant, wherein the anti-EGFR ADC is an anti-EGFR antibody conjugated to an auristatin, eg, MMAF. , eg, antibody 1. |